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Abstract
Background: The development of the nervous system involves an initially exuberant production of neurons that
make an excessive number of synaptic contacts. The initial overproduction of synapses promotes connectivity.
Hebbian competition between axons with different activities (the least active are punished) leads to the loss
of roughly half of the overproduced elements and this refines connectivity and increases specificity. The
neuromuscular junction is innervated by a single axon at the end of the synapse elimination process and,
because of its relative simplicity, has long been used as a model for studying the general principles of
synapse development. The involvement of the presynaptic muscarinic ACh autoreceptors may allow for the
direct competitive interaction between nerve endings through differential activity-dependent acetylcholine
release in the synaptic cleft. Then, the most active ending may directly punish the less active ones. Our
previous results indicate the existence in the weakest axons on the polyinnervated neonatal NMJ of an ACh
release inhibition mechanism based on mAChR coupled to protein kinase C and voltage-dependent calcium
channels. We suggest that this mechanism plays a role in the elimination of redundant neonatal synapses.
Results: Here we used confocal microscopy and quantitative morphological analysis to count the number of
brightly fluorescent axons per endplate in P7, P9 and P15 transgenic B6.Cg-Tg (Thy1-YFP)16 Jrs/J mice. We
investigate the involvement of individual mAChR M1-, M2- and M4-subtypes in the control of axonal
elimination after the Levator auris longus muscle had been exposed to agonist and antagonist in vivo. We also
analysed the role of adenosine receptor subtypes (A1 and A2A) and the tropomyosin-related kinase B receptor.
The data show that postnatal axonal elimination is a regulated multireceptor mechanism that guaranteed the
monoinnervation of the neuromuscular synapses.
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Conclusion: The three receptor sets considered (mAChR, AR and TrkB receptors) intervene in modulating the
conditions of the competition between nerve endings, possibly helping to determine the winner or the
lossers but, thereafter, the final elimination would occur with some autonomy and independently of
postsynaptic maturation.
Keywords: Motor end-plate, Motor nerve terminal, Cholinergic synapses, Neuromuscular junction
Background
The development of the nervous system involves the
initial overproduction of synapses, which promotes
connectivity, and a subsequent activity-dependent reduc-
tion in the number of synapses. This refines connectivity
and increases specificity. Hebbian competition between
axons with different activities (the least active are elimi-
nated) seems to be a characteristic of the process and
leads to the loss of roughly half of the overproduced
elements and the functional consolidation of the
remaining synapses in the adult [1, 2]. Synaptic con-
tacts are lost throughout the nervous system during
histogenesis [3, 4]. In newborn animals, the skeletal
muscle fibers are polyinnervated by several motor
axons [5] but at the end of the axonal competition, the
endplates are innervated by a single axon. Because of
its relative simplicity, the neuromuscular junction (NMJ)
has long been used as a model for studying the general
principles of synapse development in an attempt to under-
stand the synapse elimination process [2, 6–12].
Various presynaptic receptors seem to play an import-
ant role in the axonal competition leading to synapse
loss in the NMJ. The involvement of muscarinic acetyl-
choline autoreceptors (mAChRs) in the elimination
process may allow direct competitive interaction between
nerve endings through a differential activity-dependent
acetylcholine (ACh) release. Then, the more active ending
may directly punish those that are less active or reward
themselves if the suitable mAChR subtypes are present in
the competing axons. Our previous results indicate that,
in postnatal muscles, there is an ACh release inhibition
mechanism based on mAChR coupled to a PKC-VDCC
intracellular cascade. In certain weak motor axons, this
mechanism can depress ACh release and even disconnect
synapses [13–17]. We suggest that this mechanism
plays a central role in the elimination of redundant
neonatal synapses because functional axonal withdrawal
can indeed be reversed by mAChR, protein kinase C
(PKC) or voltage-dependent calcium channels (VDCC)
block [17, 18]. However, local differential effectiveness
and differential activity will determine eventual success,
since an axon that fails at one synapse (muscle cell) may
be successful at another [19], which suggests complex
regulation involving other receptors and postsynaptic-
(and glial cell) derived factors. Both neurotrophin recep-
tors (NTR) and adenosine receptors (AR) belong to lead-
ing presynaptic signalling pathways. In the adult NMJ, the
activity of one of these receptors can modulate a
given combination of spontaneous, evoked and activity-
dependent release conditions and a close dependence
between them exist [20]. These receptors and their intra-
cellular signalling may help to refine the molecular and
structural organization of the newborn synapses so that
they can acquire their mature form.
Here we investigate the involvement of individual
mAChR subtypes in the control of synapse elimination.
We also analyse the role of AR (A1 and A2A) and
trompomyosin-related kinase B receptor (TrkB). The
data show that the three receptor sets considered co-
operate in the elimination process and promote axonal
disconnection at the beginning of the second postnatal
week independently of the postsynaptic maturation of
the nicotinic receptor cluster.
Results
Postnatal elimination of nerve terminals
Normal evolution of postnatal polyneuronal innervation in
the NMJ
Figure 1 shows some representative confocal immuno-
fluorescence images of singly- and polyinnervated NMJs
from YFP (autofluorescent axons) and C57BL/J6 (axons
stained with anti neurofilament fluorescent antibody)
mice. The images show that it is feasible to accurately
count the number of axons in both preparations. Firstly,
we investigated in our experimental model the normal
postnatal elimination of the excess synaptic contacts.
Figure 2a shows axonal counts in fluorescent immuno-
histochemistry LAL preparations (average number of
axonal connections per NMJ) from B6.Cg-Tg (Thy1-YFP)
– hereafter YFP – and C57BL/J6 mice. The figure also
shows previous data [10, 21–23] from Sprague-Dawley
(SD) rats to show similarities between rodents. The histo-
gram in Fig. 2b shows the percentage of singly-, dually-
and triply- (or more) innervated synapses in YFP for the
postnatal days (P) considered without any experimental
manipulation (control, non-PBS). Because the present
work is based in subcutaneous injection procedure, we
also wanted to control that subcutaneous injection by
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itself does not affect the elimination process in the
control animals. Figure 2b also shows the percentage
of singly-, dually- and triply- (or more) innervated
synapses at P7 (n = 2315 NMJs, N= 10 mice), P9 (n = 2647
NMJs, N= 10 mice) and P15 (n = 1056 NMJs, N= 4 mice)
after two (days 5, 6), four (days 5–8) and ten (days 5–14)
subcutaneous PBS injections, respectively (control PBS).
No significant differences are observed between PBS
(the control for subcutaneous injections) and non-PBS
(without subcutaneous injection) preparations ( p >
0,05, Fisher’s test).
Stimulation of the mAChR. Effect of oxotremorine
Figure 3 shows the percentage of singly-, doubly- and
triply (or more) innervated NMJs in the untreated YFP
control mice and after 2 (P7), 4 (P9) and in some cases
10 (P15) applications (one application every day after
P5) of the mAChR agonist oxotremorine (OXO) and
such antagonists as atropine (AT), pirenzepine (PIR),
methoctramine (MET) and muscarinic toxin 3 (MT3).
We first used the potent and well characterized unselect-
ive agonist OXO. A subcutaneous application on the
YFP LAL muscle surface every day (at P5 and P6) results
in a significant acceleration at P7 of the axonal elimin-
ation process (Fig. 3a; Fisher’s test; n = 820 NMJs, N= 4
mice), because of the increase in monoinnervated NMJs
(p < 0,005) and the reduction in dual (p < 0,05) synapses.
It seems that the muscarinic mechanism, when stimu-
lated, accelerates the axonal elimination rate and transi-
tion to the monoinnervation state.
However, four applications (P5-P8) of OXO (Fig. 3b;
Fisher’s test; n = 865 NMJs, N = 4 mice) do not lead to
any significant change at P9 (p > 0,05) in monoin-
nervated and dual junctions though a small increase of
the fraction of synapses with three or more axons is
observed (p < 0,05). This indicates that the effect of
muscarinic stimulation diminishes and tends to peak
close to the normal values of axonal elimination around
four days after stimulation has begun. Therefore, there is
a window around P5-P6 in which mAChR can be forced
to accelerate synapse elimination. However, exogenous
stimulation with the agonist reveals only that muscarinic
signalling has the potential to accelerate postnatal axonal
disconnection but does not explain what the tonic
muscarinic control is like in a normal situation. There-
fore, we investigate how blocking the M1, M2 and M4
mAChR subtypes in toto or selectively (those subtypes
observed in functional developing NMJ, [13, 14, 24, 25])
can affect synapse elimination.
Unselective inhibition of mAChRs. Effect of atropine
Figure 3a shows that two subcutaneous applications of
AT (at P5 and P6) in the YFP LAL muscles analysed
at P7 significantly reduce the percentage of triple
junctions (p < 0,05), increase the percentage of dual
junctions (p < 0,01), and have no effect on the per-
centage of single junctions (Fisher’s test; n = 1343
NMJs, N = 3 mice). Thus, the rate of transition from
three to two speeds up but the overall process does
not continue to the point of significantly increasing
Fig. 1 The picture shows some representative confocal immunofluorescence images of the singly- and polyinnervated NMJ from YFP and
C57BL/J6 mice. Scale bar: 10 μm
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monoinnervation. This indicates that AT has a dual effect:
namely, it increases axon loss in triple junctions and re-
duces loss in double NMJs. It seems that NMJs or nerve
terminals of different levels of maturity have different
sensitivities and respond differently to this potent muscar-
inic pan-inhibitor.
Daily AT applications between P5 and P8 lead to a
significant retardation of axonal elimination at P9 (Fig. 3b;
Fig. 2 Postnatal evolution of polyneuronal innervation. In a, comparison of the results of axon counts in fluorencence immunohistochemistry LAL
preparations of YFP and C57BL/J6 mice. The histogram in b shows the percentage of singly-, dually- and triply- (or more) innervated synapses in
YFP animals on the postnatal days studied without any experimental manipulation (control non-PBS, without subcutaneous injection), and also at
P7, P9 and P15 after two (days 5–6), four (days 5–8) and ten (days 5–14) daily subcutaneous PBS applications respectively (control PBS). No
differences are observed between PBS and non-PBS preparations (Fisher’s test: p > 0,05)
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Fig. 3 Changes in polyneuronal innervation of the NMJ after stimulation and inhibition of the mAChR. The figure shows the percentage of
singly-, dually- and triply- (or more) innervated NMJs in the untreated YFP control mice (exposed to PBS applications) and after 2 (P7 in a), 4 (P9,
in b) and in some cases 10 (P15, in c) applications (one application every day after P5) of the mAChR agonist (ago.) oxotremorine (OXO) and such
antagonists (ant.) as atropine (AT), pirenzepine (PIR), methoctramine (MET) and muscarinic toxin 3 (MT3). Fisher’s test: * p< 0,05, ** p< 0,01, *** p< 0,005
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Fisher’s test; n = 1032 NMJs, N= 4 mice) with persistent
polyinnervation due to the higher percentage of dual junc-
tions (p < 0,005) the corresponding decrease in monoin-
nervated synapses (p < 0,005) and an almost normal
number of triple junctions (p > 0,05). This clearly indicates
that blocking the mAChR can persistently obstruct the
two-to-one transition of the elimination processs. How-
ever, unlike the OXO effect (which tends to disappear at
P9 after accelerating elimination at P7), the effect of AT
seems to be maintained throughout the period P5-P9 at
least in relation to the two-to-one transition. It seems,
then, that in normal conditions, the presynaptic muscar-
inic mechanism increases the rate of axonal loss at least in
dual junctions in the period P5-P9 and that this effect can
be increased at P7 by using an exogenous agonist.
Selective block of the mAChRs
How are the various mAChR subtypes that operate in
the postnatal NMJ (M1, M2 and M4; [16]) involved in
axonal elimination? We selectively blocked M1 (PIR), M2
(MET) and M4 (MT3) and observed the NMJ at P7
(daily applications on the LAL surface at P5 and P6,
Fig. 3a) and P9 (applications between P5-P8, Fig. 3b). At
P7 two subcutaneous PIR applications significantly re-
duced the percentage of triple (p < 0,005) and dual junc-
tions (p < 0,05) and greatly increased the percentage of
single junctions (p < 0,005, Fisher’s test; n = 915 NMJs,
N = 4 mice). Thus, both the three-to-two and the two-
to-one rates of transition accelerated considerably and
the overall elimination process speeded up. This may
indicate that in the normal situation the role of M1 is to
slow elimination down because when it is uncoupled
from PIR, the elimination process accelerates. Interest-
ingly, the M4 blocker MT3 has almost exactly the same
effect as the M1 blocker PIR (Fisher’s test; n = 895 NMJs,
N = 4 mice), whereas the M2 blocker MET does not have
a significant effect at P7 after the two subcutaneous
applications (p > 0,05, Fisher’s test; n = 1012 NMJs, N= 4
mice). As an additional control, in P7 C57BL/J6 animals
treated with MET we found the same result (Fisher’s
test; Control PBS (n = 1533 NMJs, N= 6 mice): 1 axon:
22.69 % ± 1,04 % ; 2 axons: 50.20 % ± 2.75 % ; 3 or more
axons: 27.11 % ± 3.18 %. MET application (n = 911 NMJs,
N = 3 mice): 1 axon: 22.22 % ± 2.56 % (p > 0,05); 2 axons:
50.00 % ± 2.74 % (p > 0,05); 3 or more axons: 27.78 % ± 2.38
(p > 0,05)). Thus, at P7 the ensemble M1/M4 seems to be
involved in a mechanism that delays elimination because
when it is blocked the percentage of monoinnervated junc-
tions increased and caused a fast three-to-one transition.
Nevertheless, how can it be explained that at this time
(P7) the two-to-one transition is accelerated by the
selective blockers PIR and MT3 (and not affected by
MET), but that when all mAChR subtypes were blocked
with AT this transition was partially delayed? Blocking
the whole ensemble of subtypes with AT has a somehow
diferent effect than the individual effects of mAChR
subtypes. This apparent contradiction observed with the
effects of selective and unselective pharmacological mus-
carinic inhibitory substances at P7 seems to suggest the
existence of other confluent signalling pathways that
take part in the process (see below).
However, daily applications of these substances for
four days (P5-P8) lead to a much more clearly defined
situation at P9 (Fig. 3b). As stated above, four AT appli-
cations delay elimination, maintain the number of dual
junctions and decrease the number of singly-innervated
NMJ, which indicates that the two-to-one transition is
slowing down. The same effect (even greater because of
the considerable delay in the three-to-two transition) is
obtained by blocking M1 (PIR, p < 0,005, Fisher’s test;
n = 1293 NMJs, N = 3 mice) and M2 (MET, p < 0,005,
n = 976 NMJs, N = 4 mice) but not in this case with
the M4 blocker MT3 (p > 0,05, n = 1177 NMJs, N = 4
mice). As an additional control, in P9 C57BL/J6
animals treated with MT3 we found the same result
(Fisher’s test; Control PBS (n = 1352 NMJs, N= 5 mice): 1
axon: 48.17 % ± 4.54 % ; 2 axons: 36.73 % ± 2.76 % ; 3 or
more axons: 15.10 % ± 4.97 %.MT3 aplications (n = 906
NMJs, N= 4 mice): 1 axon: 51.2 % ± 5.77 % (p > 0.05); 2
axons: 39.32 % ± 2.53 % (p > 0.05); 3 or more axons:
9.48 % ± 2.32 (p > 0.05)). These data indicate that at
this point in the elimination process, both M1 and
M2 subtypes cooperate in favouring the full sequence
of synapse elimination.
To investigate the possible persistence of the mAChR
effect throughout the period of synapse elimination, we
made daily applications of AT (the unselective mAChR
antagonist), PIR and MET (the M1 and M2 selective
antagonists that are effective at modulating axonal
elimination at P9) between P5 and P15 (in normal con-
ditions almost 90% of NMJs were monoinnervated at
P15). In spite of the continued presence of unselective
and selective inhibitors, we found that the elimination
process came to its normal conclusion by the end of the
second postnatal week (Fig. 3c; (p > 0,05, Fisher’s test;
AT: n = 720 NMJs, N = 3 mice; PIR: n = 924 NMJs, N= 3
mice; MET: n = 870 NMJs, N= 3 mice)). This reinforces
the suggestion that several signalling mechanisms between
the endings in competition cooperate (and substitute each
other) to resolve the correct synaptic connection in a
multifactorial process.
Other signalling mechanisms involved in axonal loss
Several signalling pathways connect the cells that make
synapses. Here, we studied the possible involvement of
adenosine receptors and neurotrophin receptors (here
the representative TrkB receptor for brain-derived neuro-
trophic factor (BDNF) and neurotrophin-4 (NT-4) in the
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complex period of axonal elimination around P7-P9
(Fig. 4). To the LAL muscle, we subcutaneously applied
the AR inhibitor 8SPT, the AR agonist ADO and the TrkB
blocking pathway agent TrkB-Fc to sequester endogenous
BDNF/NT-4 neurotrophins. With the 8SPT (n = 920
NMJs, N= 4 mice) and TrkB-Fc (n = 1113 NMJs, N= 4
Fig. 4 Involvement of adenosine receptors (AR) and TrkB receptors in axonal elimination. The figure shows the percentage of the singly-,
dually- and triply- (or more) innervated NMJs in the YFP control mice exposed to PBS, and after 2 (P7 in a), 4 (P9, in b) and in some cases 10
(P15, in c) applications (one application every day after P5) of the BDNF-TrkB blocking pathway agent TrkB-Fc to sequester endogenous BDNF/
NT-4 neurotrophins and the AR pan-inhibitor 8SPT and the AR agonist (ago.) ADO. We also studied axonal elimination after selectively blocking
A1R with the antagonist (ant.) DPCPX and inhibiting A2AR with SCH-58261. The control for these selective inhibitors was PBS + DMSO (not shown
in the figure) which shows no differences from PBS used as a control by itself. Fisher’s test * p < 0,05, ** p < 0,01, *** p < 0,005
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mice) blockers at P7 we observed a clear acceleration in
the three-to-two rate (Fisher’s test; 8SPT: p < 0,005; TrkB-
Fc: p < 0,05) that was very similar to the acceleration in
the two-to-one rate. These substances accelerate axonal
elimination on the NMJ and, therefore, the physiological
role in normal conditions of the AR and TrkB pathways
at P7 seems to delay the axonal loss process. This is
confirmed for the AR because exposure to the physio-
logical agonist ADO results in a significantly higher
number of triple junctions and a significant reduction
in the number of dual junctions (p < 0,005, Fisher’s
test; n = 923 NMJs, N= 4 mice). This indicates an ADO-
induced retardation of axonal elimination. Which AR
subtypes are involved in the ADO effect? We analysed
axonal elimination after selectively blocking A1R with
DPCPX (n = 1160 NMJs, N= 4 mice) or A2AR inhibition
with SCH-58261(n = 963 NMJs, N= 4 mice) (Fig. 4a). The
data show that axonal loss (the full three-to-one transi-
tion) is accelerated by both inhibitors (p < 0,005), which
indicates that in normal conditions without inhibition
both A1R and A2AR are associated with delaying loss.
Interestingly, at P9, neurotrophin signalling seems to
reverse their coupling to the axonal loss process because
TrkB-Fc (acting between P5-P8) considerably delays
elimination (resulting in more dual and fewer monoinner-
vated NMJ; p < 0,005, Fisher’s test; n = 863 NMJs, N= 4
mice), which indicates that in a normal situation BDNF/
NT-4 mediators change their role and accelerate elimin-
ation, as has been described above for the muscarinic
mechanism. At P9, the purinergic mechanism also seems
to tonically accelerate axonal elimination to the maximum
rate because the AR pan-inhibitor 8SPT delays the process
(an effect of the A1R and A2AR, Fig. 4b; Fisher’s test;
n > 900 NMJs, N = 4 mice in each case) with no effect
of the agonist ADO (p > 0,05, n = 908 NMJs, N= 4 mice).
Therefore, it seems that AR may behave biphasically in
the critical period between 5-9 postnatal days. An initial
delay in axonal loss at P7 (an A1R- and A2AR-mediated
effect which can be reinforced by exogenously added
ADO) is followed by an A1R- and A2AR-mediated tonic
acceleration at P9.
To sum up, the two receptor sets (TrkB and AR)
initially delay (P7) axonal loss but promote axonal dis-
connection at the beginning of the second postnatal
week (P9) as mAChRs do. Figure 10 shows a graphic
representation of these actions.
However, the experimental groups also differ with re-
spect to the duration of receptor perturbation (two, four,
and ten injections at P7, P9, and P15, respectively). Some
effects may therefore be due to different durations of
receptor inhibition. For instance, compensatory mecha-
nisms may have more or less time to counteract receptor
blockade. Thus, it is interesting to evaluate synapse devel-
opment at different time points after inhibiting receptors
for the same time. For the action of some blockers (MET,
DPCPX and TrkB-Fc), we probe synapse development at
P9 after inhibiting receptors for only two days (from P7-
P9). The results show that the three blockers studied
significantly reduce the percentatge of the monoinner-
vated junctions (with respect to the untreated control at
P9) independently of their application during four or only
two days before the observation at P9. This data reinforce
the idea that the receptors role, in normal conditions
without the inhibitors, can be to accelerate axonal loss.
Interestingly, there are some differences between the
blockers. The M2 blocker MET produces the same effect
after four or two days (25.6 ± 1.04 % and 27.2 ± 1.1 %
monoinnervated synapses respectively, Fisher’s test,
p > 0,05). However, the A1 blocker DPCPX and the
TrkB pathway blocker TrkB-Fc, significantly reduce
the monoinnervated synapses even more after two
days than after four days of application over the LAL
muscle surface (DPCPX: two days 33.7 ± 1.16 %, four days
39.8 ± 1.09 %, p < 0,05; TrkB-Fc: two days 30.9 ± 1.12 %,
four days 42.75 ± 1.07 %, Fisher’s test, p < 0,05). These data
reinforce our interpretation that the M2 receptors start to
accelerate axonal elimination around P7 whereas A1 and
TrkB are involved in the initial delay (P5-P7) of axonal
loss before shifting to promote axonal disconnection at
the beginning of the second postnatal week (P9). The
absence of the A1 and TrkB inhibition between P5-P7
results in a strong effect of the inhibitors when applied
between P7-P9.
To assess the overall capacity of the considered sig-
naling on axonal elimination, we investigate the overall
effect of prolonged global receptor perturbation on axon
number at P15. We studied axon number after more
prolonged general block of mAChRs (AT, see above
Fig. 3c), ARs (8SPT) and TrkBRs (TrkB-Fc) and found
that in all cases, in spite of the continued presence of
the inhibitors, monoinnervation is achieved in about 90 %
of NMJ at P15 (Fig. 4c; (p > 0,05, Fisher’s test; TrkB-Fc:
n = 825 NMJs, N = 3 mice; 8SPT: n = 720 NMJs, N = 3
mice)). We conclude that the modulation of axonal
competition and the final process of axonal disconnection
and loss seems differentially regulated.
Finally, we made some preliminary experiments to
show a real cooperation between the receptors. For this
purpose we selected receptors which perturbation produces
a strong effect on axonal loss at P9 and applied simultan-
eously their inhibitors in a LAL muscle in four animals. We
associated one AR blocker (DPCPX or SCH-58261) with
the M1 blocker PIR. We found that both DPCPX
and SCH-58261 add their individual delaying effect
on axonal loss to the delaying effect of PIR resulting
in 58 % and 36 % respectively less monoinnervated
junctions that with PIR only (monoinnervated NMJ
after PIR, 39 ± 1.1 %; after PIR + DPCPX, 16.4 ± 1.08 %;
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after PIR + SCH-58261, 24.8 ± 0.8 %. The two inhibitor
associations differ significatively from the PIR only
effect, p < 0,005).
Postsynaptic receptors cluster during postnatal
maturation
mAChR influence on the postsynaptic maturation
We analysed the morphological maturation of the post-
synaptic apparatus in the same experimental conditions
as those in the previous study on axon loss. The axonal
elimination process is accompanied by changes in the
morphology of the nicotinic ACh receptor (nAChR)
clusters in the postsynaptic component. On the basis of
criteria from previous studies on developing mammalian
NMJs [23, 26–30], the following maturation stages
(MS1–MS4) were defined (Fig. 5a). As normal matur-
ation takes place, changes in the nAChR distribution
transform the uniform nAChR oval plaque with an
indistinct boundary seen at birth (MS1) into an elon-
gated plaque with a few hints of heterogeneities in
receptor density (MS2). This then changes into clusters
with small areas of low nAChR density appearing as
holes (MS3) that are not innervated. This morphology
leads to an increasingly structured pattern of fluores-
cently labelled independent primary gutters (MS4) below
the nerve terminals. Figure 5b shows the percentages of
the MS1-MS4 nAChR clusters plotted at days P5-P15.
Stimulation and inhibition of the mAChRs
Figure 6 shows the percentage of MS1-MS4 clusters in
the NMJ of the untreated YFP control mice (PBS) and
after 2 (P7, Fig. 6a), 4 (P9, Fig. 6b) and 10 (P15, Fig. 6c)
applications of the muscarinic substances considered.
Figure 7a, b and c also show the percentage of MS3
clusters (postsynaptic clusters in advanced morpho-
logical maturation) with one, two or three (or more)
axons for each day. This percentage can be taken as an
indication of the correspondence between pre- and post-
synaptic maturation. After the mAChR antagonists AT,
PIR and MET (MT3 does not unambiguously modify
the postsynaptic clusters) had been applied for two days,
at P7 we found changes in the morphological maturation
of the postsynaptic apparatus. Generally there was a high
percentage of differentiated MS3 clusters (p < 0,005,
Fisher’s test) and fewer MS1 and MS2 (p < 0,005)
(Fig. 6a). Interestingly, many of these MS3 clusters are
still innervated by 2–3 axons (Fig. 7a), which indicates
some imbalance in the appropiate pre- and postsynaptic
correspondence. The fact that postsynaptic maturation
accelerates after muscarinic inhibition supports the notion
Fig. 5 Postnatal morphological maturation of the postsynaptic apparatus. The axonal elimination process is accompanied by changes in the
morphology of the nAChR clusters in the postsynaptic membrane. a, the following maturation stages (MS1–MS4) were defined. MS1: Uniform
nAChR oval plaque with an indistinct boundary seen in the majority of NMJs at birth. A uniformly distributed porosity can be observed within
this plaque. MS2: nAChR elongated oval plaque with a few hints of inhomogeneities in receptor density. The nAChRs are denser on a few narrow
ridges that occur within the plaque. MS3: An oval nAChR plaque with one or more fluorescence-free “holes.” These holes are not innervated. MS4:
The oval nAChR areas have been transformed into a more mature branched pattern with a moderately convoluted external border and high and
low receptor density areas. The edge of the holes usually has a high density of receptors. Scale bar: 10 μm. b, shows the percentages of the
MS1-MS4 nAChR clusters plotted in the interval P5-P15 days
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that in normal conditions (without inhibition) the M1 and
M2 subtypes have a tonic role and delay maturation.
Because OXO does not have a definite significant effect
(p > 0,05) (Fig. 6a), the tonic muscarinic effect may operate
at close to its maximum rate.
At P9, the selective muscarinic drugs PIR, MET
and MT3 accelerated cluster maturation, and pro-
duced fewer MS1 and more MS3 clusters (Fisher’s
test; for MS3: PIR (p < 0,005); MET i MT3 (p < 0,05);
even MS4 for MT3; see Fig. 6b), many of which (for
AT, PIR and MET experiments) were innervated by
2–3 axons as they were at P7 (Fig. 7b). This also
indicates that at P9 the M1, M2 and M4 subtypes are
involved in delaying the normal maturation process
in normal conditions. However, AT does not change
the normal percentage of the cluster subtypes
(though the MS3 subtype is also innervated by 2–3
axons, p > 0,05) and OXO moderately accelerates
maturation (by reducing MS1 (p < 0,005) and increasing
the MS2 subtype, p < 0,01). Thus, the use of the subtype-
unselective drugs AT and OXO reveal the complex
involvement of the mAChRs in the morphological
maturation process of the postsynaptic receptor clus-
ters. The coincident contribution of other signalling
will be considered below.
With the unselective mAChR antagonist AT and the
selective M1 and M2 muscarinic inhibitors, and spe-
cially with PIR, we observed at P15 that postsynaptic
maturation seems to be slower and partially retained
at the MS3 subtype (Fig. 6c) though most MS3 are
Fig. 6 Maturation of postsynaptic nAChR clusters after stimulation and inhibition of mAChRs. Percentage of MS1-MS4 clusters in the NMJ of
untreated YFP control mice (exposed to PBS), and after 2 (P7, in a), 4 (P9, in b) and in some cases 10 (P15 in c) applications of the muscarinic
substances considered: OXO, AT, PIR, MET and MT3. Fisher’s test * p < 0,05, ** p < 0,01, *** p < 0,005
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already monoinnervated in the presence of AT, PIR
and MET (Fig. 7c).
Thus, as far as postsynaptic clusters are concerned,
in normal conditions mAChRs tend to produce some
delay in maturation throughout the P5-P9 period
and this effect is extended at P15 when axonal
elimination is almost complete whether muscarinic
modulators are used or not.
Fig. 7 Pre- and postsynaptic maturation in the MS3 clusters after stimulation and inhibition of the mAChRs. For each day considered (P7 in a, P9
in b and P15 in c) the figure shows the percentage of MS3 clusters (the oval nAChR plaques with fluorescence-free holes that mature at a faster
rate) with one, two and three or more axons as an indication of the appropiate correspondence of the pre- and postsynaptic maturation. Fisher’s
test * p < 0,05, ** p < 0,01, *** p < 0,005
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Other signalling mechanisms involved in postsynaptic
maturation
Figure 8a shows that after two days of using TrkB-Fc to
sequester endogenous BDNF/NT-4, nAChR maturation
is delayed at P7 because of the persistence of many
MS1 clusters (p < 0,005, Fisher’s test). This indicates
that the normal stimulation of the TrkB pathway
promotes postsynaptic maturation at around P7. This
tendency is reversed at P9 after four days of exposure
to TrkB-Fc because of the clear increase in the MS3
subtype with respect to the untreated control (p < 0,05,
Fig. 8b). In addition, many of these MS3 clusters are poly-
innervated (with three or more axons, p < 0,005, Fig. 9b).
Ten applications (one application every day after P5) of
Fig. 8 Involvement of the AR and TrkB receptors in the morphological maturation of the postsynaptic apparatus. The figure shows the
percentage of the MS1-MS4 clusters in the NMJ of the untreated YFP control mice (exposed to PBS), and after 2 (P7 in a), 4 (P9, in b) and in some
cases 10 (P15, in c) applications (one application every day after P5) of the TrkB blocking chimera TrkB-Fc, the AR pan-inhibitor 8SPT and the AR
agonist ADO. We also studied axonal elimination after selectively blocking A1R with DPCPX and inhibiting A2AR with SCH-58261. Fisher’s test:
* p < 0,05, ** p < 0,01, *** p < 0,005
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TrkB-Fc reveal some delay of the postsynaptic mat-
uration at P15 (increased MS3 and less MS4 clus-
ters, Fig. 8c). Thus, the TrkB pathway seems to have
a complex effect on postsynaptic maturation (accel-
erated at P7, delayed at P9 and accelerated once
again thereafter).
With regard to the AR pathway, at P7 we found that the
unselective antagonist 8SPT had no effect on the matur-
ation of postsynaptic clusters (p > 0,05, Fisher’s test Fig. 8a)
although when 8SPT was applied in the period P5-P8 (ob-
servation at P9, Fig. 8b) MS2 clusters increased and MS1
and MS3 clusters decreased (p < 0,005), which indicates
Fig. 9 Pre- and postsynaptic maturation in the MS3 clusters. AR and TrkB pathways modification. For each day considered (P7 in a, P9 in b and
P15 in c), the figure shows the percentage of MS3 clusters with one, two and three or more axons as an indication of the appropiate
correspondence of the pre- and postsynaptic maturation. Fisher’s test: * p < 0,05, ** p < 0,01, *** p < 0,005
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some delay in the transition from MS2 to MS3. Also, many
of the few MS3 clusters remain polyinnervated with two or
three axons (p < 0,005, Fig. 9b). Interestingly, we observed
that after daily applications of 8SPT between P5 and P15
the postsynaptic maturation seems to be partially retained
at the MS3 subtype (Fig. 8c). Thus, AR in normal condi-
tions without inhibition can accelerate maturation some-
what during the P7-P9 period. Interestingly, exposure of
the LAL muscle to the agonist ADO does not unambigu-
ously change the normal distribution of the clusters at P7
(although it decreases MS3 slightly and a number of these
clusters are innervated by three or more axons [p < 0,01,
Figs. 8a and 9a]) and P9 (although there is a slight decrease
in MS1, p < 0,01). This indicates that the tonic effect of the
AR manifested by using 8SPT can not be clearly changed
with exogenously added agonist. Which AR subtypes are
involved in the tonic effect of endogenous ADO? We
analysed the maturation of nAChR clusters after selective
block of A1R with DPCPX or A2AR block with SCH-58261.
Our data indicate that blocking A1R at P7 and both A1R
and A2AR at P9 delays the maturation of normal clusters
meaning that both receptor subtypes can accelerate post-
synaptic maturation in normal conditions.
The diagram in Fig. 10 is a graphic representation of
the influence of the mAChRs, and the AR and TrkB
receptors on postnatal axonal elimination and postsyn-
aptic maturation.
Discussion
The main observation of the present study is that the
coordinated action of the mAChRs (M1, M2 and M4), AR
(A1R and A2AR) and TrkB signalling modulates the condi-
tions of axonal competition and promotes (around P7-P9)
the disconnection of supernumerary nerve endings.
Presynaptic mAChRs M1-, M2- and M4-subtypes modulate
axonal loss
Although there is not agreement about whether all
mAChR subtypes are present in the NMJ [25, 31], some
of these receptors play a role in ACh release both during
development [18, 21, 32] and in the adult [32, 33]. In
P6-P7 mice, we observed that M1 and M4 subtypes are
involved in a mechanism that delays axonal elimination.
However, the action of all muscarinic receptors as a whole
indicates that the muscarinic mechanism increases the
rate of axonal loss in dual junctions and, therefore, the
final transition to the monoinnervation. It seems that
NMJs with different maturation levels have different sensi-
tivities to muscarinic regulation. The relative levels of these
receptors or differences in turnover rate may contribute to
the different effects observed. Using Western blotting we
observed that in the adult, M1, M2, M3 and M4 receptors
are more abundant than in the newborn [25]. In fact,
changes in the expression of muscarinic receptors during
development have been described in embryonic chick heart
and retina [34], in carotid body, petrosal and superior cer-
vical ganglion of the cat [35] and in rat brain [36]. In
addition there are differences in the internalization and
turnover of the mAChR family members [37, 38] and endo-
cytosis may favour the coupling of the receptors to differ-
ent signal transduction cascades [39].
However, the M1-M2 subtype pair (in substitution of
the M1-M4 pair) cooperates to favour the full sequence
of synapse elimination at P9 (the three-to-one axon
transition). The delayed two-to-one transition induced
by AT at P7 (which reveals accelerated axonal elimin-
ation in normal conditions without the inhibitor) may be
interpreted as an early manifestation of the consistent
mAChR-modulated axonal loss that is fully manifested
at P9. The muscarinic mechanism appears to operate at
close to maximum capacity and, therefore, may not be
able to increase its efficacy beyond P7 with agonists like
OXO. Interestingly, in spite of the continued presence of
the M1 and M2 inhibitors, the elimination process comes
to its normal conclusion at the end of the second postna-
tal week (P15). This suggests that other signaling mecha-
nisms help to resolve the correct synaptic connectivity.
Alternatively, M1 and M2 signaling may be not required at
Fig. 10 Influence of the mAChR, AR and TrkB receptors on postnatal axonal elimination and synaptic maturation
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all for the final step of axonal elimination because the
receptor inhibitors produce only transient perturbations
in elimination but axon los is completed normally around
P15. Our interpretation is that all considered receptors
(see later) intervene in modulating the conditions of the
competition between nerve endings, possibly helping to
determine the winner or the lossers but, thereafter, the
time and conditions of the final elimination would occur
with some autonomy.
In summary, the results show that a tonic muscarinic
mechanism initially delays axonal elimination (a selective
M1-M4 effect). However, the overall mAChR effect may
accelerate the last phase of axonal disconnection, the
two-to-one transition. Thereafter the muscarinic effect
at around P9 clearly promotes elimination of all super-
numerary nerve terminals (an M1-M2 effect).
Which mAChR subtypes couple to regulate ACh release?
In the mature NMJ, M1 and M2 mAChRs modulate evoked
transmitter release by positive and negative feedbacks, re-
spectively [13, 40]. M2 is more prevalent [20, 31]. During
synaptogenesis, [13, 14, 41], in the monoinnervated junc-
tions and the strong terminal in dually innervated junctions
both M1 and M2 are coupled to potentiate ACh release.
However, in the weakest nerve terminal in dual junctions
only M2 potentiates release whereas M1 and M4 couple to
inhibit ACh secretion. A mAChR-PKC-VDCC cascade is
involved in controlling ACh release in the weak ending.
Blocking PKC, VDCCs (P/Q-, N- or L-type or Ca2+ influx)
or mAChRs (M1- and/or M4-subtypes) can lead to similar
percentage increases in the size of the synaptic potentials
evoked by weak axons [15–17].
How are related the release capacity of the strong and
weak endings and the loss of axons described here? At
P7, the release capacity of the weakest endings was
increased by the inhibitors PIR and MT3, whereas ACh
release from the strong ending was reduced or un-
affected [16]. Thus, the difference in ACh release be-
tween the strong and weak nerve endings is reduced,
and this fact may change the competitive conditions of
the nerve terminals. We do not know exactly how is the
ACh release capacity of the weak and strong endings in
the LAL muscle at P9. However, between P7 and P9, the
percentage of polyinnervated junctions changes only by
about 10%. The configuration of mAChR in the monoin-
nervated synapses is not mature until P15 [13], which
suggests that the competitive interactions between axons
peak at around P9 and their release capacity is probably
not very different from what it is at P7. If this is so, the
reduction of the competitive advantage and disadvantage
linked to ACh release of the strong and weak endings
produced by PIR and the reduccion of the strength of
the different axons produced by MET (MT3 does not
play at P9) may considerably delay axonal loss. We
found here that this is the case.
Contribution of AR and TrkB receptor pathways
Several data suggest the involvement of other receptors.
The mAChR agents alter the time course of the synapse
elimination but not its final chronology. Experimental
manipulations of the PKC/PKA pathways can also
change the time course but not the final conclusion of
synapse elimination [23, 32, 42, 43]. This indicates that
different receptors with their intracellular mechanisms
can be used in the process of synapse elimination.
AR are present in the motor terminals of the newborn
and adult NMJs [44, 45]. These receptors can collaborate
with mAChR to reduce depression during repetitive activity
[44, 46, 47]. During development, low extracellular concen-
trations of ADO may activate both A1R and A2AR and have
a facilitatory action on ACh release [48]. Our results show
that mAChR and AR delay axonal loss at P7 (although
mAChR accelerate the last phase of axonal disconnection)
but accelerate it at P9. The results showing an additive
effect between M1 and A1 or A2A are an indication of the
cooperation between at least these receptors.
The BDNF-TrkB pathway also plays a biphasic role. Judg-
ing from the effect of the TrkB-IgG chimera, BDNF initially
delays elimination and subsequently accelerates it. Neuro-
trophins and their receptors in muscle and nerve are
expressed in both development and adulthood [49–54].
Low doses of BDNF rapidly induce a TrkB-dependent po-
tentiation at developing NMJs in culture. In developing
muscles, BDNF increases ACh release in both the weak
and strong endings at P6-P7 [55]. In addition, exogenous
BDNF increases the percentage of functional polyinner-
vated junctions [17]. Interestingly, exogenous BDNF infu-
sion delayed synapse elimination in the mouse LAL muscle
[56] The delaying effect of the TrkB pathway on axonal
elimination at P7 described here may be releated with the
BDNF potentiation of the weakest endings about to be
eliminated. However, blocking the TrkB receptor or neu-
tralizing endogenous BDNF with the TrkB-IgG chimera at
P7 does not affect the quantal content of the weak endings
but increases release in the strong ending, which suggests
that endogenous BDNF, in this developmental period, may
surprisingly reduce release in the strongest ending [55].
The delaying effect of the TrkB pathway on axonal elimin-
ation at P7 may be related to the BDNF-mediated lesser re-
lease and presumed lesser competitive force of the strong
axon. The TrkB pathway accelerate elimination at P9. The
progressive maturation of the NMJ at P9 may change the
operation conditions of the BDNF-TrkB pathway in the
strongest endings resulting in more efficient competition
and axonal elimination [55, 57].
Relation between mAChR, AR and TrkB pathways
The mAChR, AR and TrkB pathways share a link mediated
by the set phospholipase C (PLC)-phosphatidylinositol 4,5-
bisphosphate (PIP2)-diacylglycerol (DAG)-protein kinase C
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(PKC), which modulates P/Q-type VDCC [40, 58]. Interest-
ingly, PKC couples to potentiate ACh release in the adult
monoinnervated NMJ, in the strong ending in developing
dual junctions and in the solitary ending of the recently
monoinnervated junctions at the end of developmental
maturation. However, reduces release in the weakest axons
in dual junctions and, therefore, PKC may be determinant
in the regulation of axonal loss [18].
Involvement of the mAChR, AR and TrkB in the
maturation of nAChR clusters
mAChR [25], AR [44] and TrkB receptors [55] are
present in the postsynaptic site of NMJs and are in-
volved in organizing them [50, 59–61]. The changes we
observed may be caused by the pharmacological tools
directly acting on these receptors, as a side-effect of a
primary effect on the axonal elimination rate or a
combination of the two mechanisms. The first change in
synapse elimination may be a reduction in the quantal
efficacy because of a local decrease in nAChR density
[62]. This postsynaptic change may begin before the
overlying axon withdraws [63]. However, polyneuronal
innervation decreases considerably at a time when rela-
tively few postsynaptic nAChR are lost [10, 23]. We
found here that several situations of increased axon loss
or retention do not coincide with the maturation of the
nAChR clústers, which suggests independent regulation.
Interestingly, prolonged M1 and M2 inhibition results in
a defect in postsynaptic maturation at P15. Especially,
M1 perturbation had a strong effect. This finding sug-
gests a requirement for M1 and M2 signaling in postsyn-
aptic maturation and occurs when axon loss has been
completed. In addition, AR block with 8SPT and TrkB
pathway block with the TrkB-Fc chimera, similarly delay
postsynaptic maturation at P15 (in all cases less MS4
mature nAChR clusters) indicating also the need of
these signalling pathways in postsynaptic maturation.
Selective nAChR-phosphorylation by PKC and PKA is
one of the causes of nAChR dispersion and stability,
respectively [64–66]. An activity-dependent coordinated
mAChR-AR-TrkB effect on these postsynaptic kinases
could be a key mechanism in NMJ maturation.
Conclusion
Synaptic contacts are lost throughout the nervous system
during both histogenesis and ageing and experience-
dependent neuronal plasticity requires maintenance of
newly formed synapses, while others are eliminated. We
investigate the involvement of muscarinic, purinergic and
neurotrophin receptor signaling in developmental synapse
elimination. The three receptor sets intervene in modulat-
ing the conditions of the competition between nerve
endings, possibly helping to determine the winner or the
lossers but, thereafter, the final elimination would occur




Transgenic B6.Cg-Tg (Thy1-YFP)16 Jrs/J mice were used
(The Jackson Laboratory). Transgenic mice express
spectral variants of GFP (yellow-YFP) at high levels in
motor and sensory neurons, as well as in subsets of
central neurons. Axons are brightly fluorescent all the
way to the terminals. No expression is detectable in
nonneural cells. All experiments were conducted on Thy1-
YFP-expressing mice. In some cases, we check our results
with C57BL/6J mice (The Jackson Laboratory).
Experiments were performed on the Levator auris longus
(LAL). Neonatal pups of either sex (4–30 days) were ob-
tained and the date of birth was designated postnatal day 0
(P0). We minimized the variability in our measurements by
carefully monitoring the timing of conception. Also, the
weights of the individuals were within 5 % of the mean for
a given day after conception. The mice were cared for in ac-
cordance with the guidelines of the European Community’s
Council Directive of 24 November 1986 (86/609/EEC) for
the humane treatment of laboratory animals. All experi-
ments on animals have been reviewed and approved by the
Animal Research Committee of the Universitat Rovira i
Virgili (Reference number: 0233).
Injection procedure
The newborn mice were anesthetized with 2 % tribro-
moethanol (0.15 ml/10 g body weight, i.p.). Under aseptic
conditions, various solutions (antagonists and agonists of
the considered receptors) were administered in 50 μl of
sterile physiological saline or dimethyl sulfoxide (DMSO)
by subcutaneous injection over the LAL external surface as
described elsewhere [22]. The animals received 2, 4 or 10
injections from postnatal day 5, and the LAL muscles were
studied on days 7, 9 and 15. The solutions were adminis-
tered at a concentration in accordance with the previously
reported biological action of the substance [14, 55, 67].
Tissue preparation and histochemistry
Neonatal pups were given a lethal dose of 2 % tribro-
moethanol. Their heads were removed and fixed in 4 %
paraformaldehyde for 1.5 h. After washing in phosphate-
buffered saline (PBS), LAL muscles were removed and
post-fixed for 45 minutes. After washing in PBS, Thy1-
YFP LAL muscles were incubated in PBS containing a 1/
800 dilution of 1μg/ml tetramethylrhodamine conjugated
α-bungarotoxin (Molecular Probes, Eugene, OR) for 1h at
room temperature.
Double immunofluorescence and confocal analysis
were performed on the C57BL/6J LAL muscle. Whole
mounts of LAL were processed to detect the axons with
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an antibody against 200-kD neurofilamentprotein and
postsynaptic nicotinic acetylcholine receptors (nAChRs)
with TRITC-α- BTX (Molecular Probes, Eugene, OR).
Muscles were incubated overnight only with the rabbit
antibody against 200-kD neurofilament (1:1,000; Sigma)
in 1 % bovine serum albumin (BSA). The appropriate
secondary antibody (conjugated with Alexa-fluor 488)
donkey anti-rabbit (Molecular Probes) was added and
incubated for 4 h. The antibody specificity was tested by
incubation in the absence of primary antibody. At least
three muscles were used as negative controls (not
shown). Whole muscles were mounted in Mowiol with
p-phenylenediamide (Sigma).
Morphological analysis and Confocal microscopy
NMJs were analyzed using an inverted Nikon TE-2000
fluorescent microscope (Nikon, Tokyo, Japan) connected
to a personal computer running image analysis software
(ACT-1, Nikon). The number of axons per endplate was
counted. Because of the difficulty in determining the
exact number of axonal inputs for each nAChR cluster
when more than two axons converged at the same
synaptic site, we classified the NMJs into three groups
only: junctions that were monoinnervated, doubly inner-
vated, or innervated by three or more terminal axons.
These data enabled us to calculate the “average number
of axonal inputs” and the “percentage of polyneuronal
innervation” for all fibers receiving two or more axons.
In PBS, DMSO control experiments or untreated ani-
mals, we determined the number of axons per endplate
between days 5 to 30 and the postsynaptic nAChR
cluster morphology on days 5, 7, 9, 10 and 15. Animals
were injected with PBS or DMSO over the LAL muscle.
The injections were performed from day 5 and the
animals sacrificed on days 7, 9, and 15. No differences
were found between the muscles injected or not with
PBS, either in the nAChR cluster morphology or the
number of axons per endplate, thus indicating that the
injection procedure did not in itself induce changes in
the overall morphology of the motor endplate and nerve
terminals. The final concentration of DMSO in control
and drug-treated preparations was 0.1% (v/v). In control
experiments, this concentration of DMSO did not affect
any of the parameters studied (data not shown).
To determine the effect of different treatments on the
maturity of nAChR clusters at the NMJ during the
period in which polyneuronal innervation is being elimi-
nated, the maturation of the clusters was divided into
four morphological stages (MS1–MS4) on the basis of
criteria from previous studies of developing mammalian
NMJs [23, 26, 27, 29] (Fig. 5). MS1: Uniform nAChR
oval plaque with an indistinct boundary seen in the
majority of NMJs at birth. A uniformly distributed por-
osity can be observed within this plaque. MS2: nAChR
elongated oval plaque with a few hints of inhomogenei-
ties in receptor density. The nAChRs are denser on a
few narrow ridges within the plaque. MS3: An oval
nAChR plaque with one or more fluorescence-free
“holes.” These holes are not innervated. MS4: The oval
nAChR areas have been transformed into a more mature
branched pattern with a moderately convoluted external
border and high and low receptor density areas. The
edge of the holes usually has a high density of receptors.
High-resolution confocal images were obtained with a
63x oil objective (1.4 numerical aperture) on a Nikon
TE-2000 confocal microscope. Z stacks were obtained at
0.5-μm step size for depths of 20–40 μm, and additional
optical sections above and below each junction were
collected to ensure that the entire synapse was included.
Statistical analysis
All NMJs visible in their entirety were scored, with a
minimum of 100 per muscle. At least six muscles were
studied for each age and condition examined. Fisher’s
test was applied to compare percentages. The criterion
for statistical significance was p < 0.05. The categories
were scored and the counting was performed by a
person with no knowledge of the age or treatment of the
animals. The data are presented as mean ± SD.
Drugs
Purinergic agents
Non-selective AR agonists and antagonists The stock
solution of adenosine 5′-triphosphate disodium salt hy-
drate (ADO; A9251, Sigma-Aldrich, St. Louis, MO) was
made up as a 100 mM solution in deionized water. The
stock solution of 8-(p-sulfophenyl)theophylline (8-SPT;
A013, Sigma-Aldrich, St. Louis, MO) was made up as a
100 μM solution also in deionized water. The working
solutions were adenosine (25μM) and 8-SPT (100 μM).
Selective A1 R and A2A R antagonists The stock solu-
tions were 8-cyclopentyl-1,3-dipropylxanthine (DPCPX;
C101, Sigma-Aldrich) 50 mM, and 2-(2-furanyl)-7-(2-
phenylethyl)-7H-pyrazolo[4,3-e] [1, 2, 4] triazolo[1,5-
c]pyrimidin-5-amine (SCH-58261; 2270, Tocris, Bristol,
UK) 100 mM, both dissolved in DMSO. Working solu-
tions were DPCPX (100 nM) and SCH-58261 (50 nM).
Muscarinic agents
Non-selective mAChR agonists and antagonists The
stock solutions were oxotremorine M (OXO; O100,
Sigma - Aldrich, St. Louis, MO) 50 mM; atropine (AT;
A0132, Sigma - Aldrich, St. Louis, MO) 200 μM both
dissolved in deionized water. Working solutions were
oxotremorine M (1μM) and atropine (2μM).
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Selective M1, M2 and M4 mAChR antagonists The
stock solutions were pirenzepine dihydrochloride (PIR;
1071, Tocris Bioscience) 10 mM; methoctramine (MET;
M105, Sigma – Aldrich, St. Louis, MO) 1 mM; muscarinic
toxin 3 (MT-3; M-140, Alomone Labs) 50 μM. The
working solutions used were pirenzepine (10 μM), meth-
octramine (1μM), and muscarinic toxin 3 (100 nM).
TrkB receptor-related agent
The following stock solutions was used: recombinant
human trkB/Fc Chimera (trkB-Fc; 688-TK;R&D Systems),
100μg/ml. Working solution was trkB-Fc 5μg/ml.
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